The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. For example, the Group significantly contributed to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
New publication: “Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report”12/12/2018
Dr Basu and colleagues presented comparative data about the performance of colorectal cancer (CRC) screening programmes in the European Union Member States. This is the first report presenting comparative data about performance of ongoing CRC organised screening programmes, using quality indicators recommended by international guidelines. This analysis documented a large variability, which might result in potential variations in the future balance of benefits and harms of the programmes.View the publication.
Meeting: “The Cervical Cancer Working Group on Surveillance and Monitoring” WHO, Geneva, Switzerland11/12/2018 – 12/12/2018
Dr Basu participated in the meeting of the Cervical Cancer Working Group on Surveillance and Monitoring in Geneva, Switzerland, organized by WHO.
Conferences: International Cancer Research and Cancer Control and Japanese Association of Cancer Registries, Tokyo, Japan07/12/2018
Dr Basu presented during the seminar on International Cancer Research and Cancer Control organized by the National Cancer Center (NCC), Japan and gave a lecture at the Japanese Association of Cancer Registries (JACR) Annual Symposium in Tokyo, Japan.
|Senore C., Basu P., Anttila A., Ponti A., Tomatis M., Vale D.B., Ronco G., Soerjomataram I., Primic-Žakelj M., Riggi E., Dillner J., Elfstrom M.K., Lonnberg S., Sankaranarayanan R., Segnan N. Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut. 2018 Dec 10.|
|Utada M., Chernyavskiy P. Lee W.J., Franceschi S., Sauvaget C., Berrington de Gonzalez A., Withrow D.R. Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer. 2018 Nov 25.|
|Mandal R, Basu P. Cancer screening and early diagnosis in low and middle income countries: Current situation and future perspectives. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Oct 23.|